BWL
MBRX icon

Bogart Wealth LLC’s Moleculin Biotech MBRX Stock Holding History

Bogart Wealth LLC’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12
Closed -$159 – 1646
2025
Q3 		$159 Hold
12
– – ﹤0.01% 1491
2025
Q2 		$91 Hold
12
– – ﹤0.01% 1424
2025
Q1 		$292 Hold
12
– – ﹤0.01% 1335
2024
Q4 		$510 Buy
+12
New +$727 ﹤0.01% 1273

Other funds holding MBRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
PWPS
Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Bogart Wealth LLC's MBRX Position: Q4 2025 in Review

Bogart Wealth LLC sold out of Moleculin Biotech (MBRX) in Q4 2025, closing a stake of 12 shares — an estimated $159 sold.

Bogart Wealth LLC first reported a position in MBRX in Q4 2024 and held it in 4 quarters. The position peaked at $510 in Q4 2024. 17 funds tracked by Wall St. Rank hold MBRX as of Q4 2025.

  • Bogart Wealth LLC reported no remaining Moleculin Biotech position as of Q4 2025 after selling out during the quarter.
  • Bogart Wealth LLC sold 12 Moleculin Biotech shares in Q4 2025, an estimated $159.
  • Bogart Wealth LLC first reported a position in Moleculin Biotech in Q4 2024 and held it in 4 quarters.
  • Bogart Wealth LLC's Moleculin Biotech position peaked at $510 in Q4 2024.
  • 17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2025.

Based on Bogart Wealth LLC's 13F filing for Q4 2025, filed 30 Jan 2026.